PIPAC is a new surgical procedure and a viable treatment option for PSM patients, due to promising therapeutic outcomes, minimal invasiveness, limited surgical morbidity, and systemic toxicity side effects. However, its implementation throughout hospitals is hard to obtain due to its fragile economical sustainability. A retrospective health economic analysis was conducted in order to evaluate the cost of hospitalization for patients undergoing PIPAC treatment at Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, in Rome. The average cost of a PIPAC procedure was defined based on the cost of surgery (cost of surgical material, operating room, intraperitoneal chemotherapy), hospital stay, diagnostic examinations, and drugs used during the stay. A total of 493 PIPAC procedures were performed on 222 patients with peritoneal metastases or primary peritoneal cancer from 2017 to 2023. Since the mean remuneration for each PIPAC hospitalization is €5916 and the mean expenditure per hospitalization is €6538, this results in an operating profit per PIPAC hospitalization of −€622. The reimbursement of PIPAC treatment by the Italian National Health System currently only partially covers the hospital’s costs. Development of specific codes and adequate reimbursement for PIPAC by recognizing this procedure as a proper treatment for peritoneal carcinomatosis is essential.
腹腔内加压气溶胶化疗（PIPAC）作为一种新兴外科技术，因其良好的治疗效果、微创性、较低的手术并发症及全身毒性副作用，已成为腹膜转移瘤患者可行的治疗选择。然而，由于该技术经济可持续性较为脆弱，其在医院范围内的推广实施面临困难。本研究通过回顾性卫生经济学分析，评估了罗马杰梅利大学医院基金会IRCCS收治的PIPAC患者住院成本。PIPAC手术平均成本根据手术费用（手术耗材、手术室、腹腔内化疗）、住院时长、诊断检查及住院期间用药综合核算。2017年至2023年间，共对222例腹膜转移或原发性腹膜癌患者实施了493次PIPAC治疗。数据显示，每次PIPAC住院的平均医保偿付额为5916欧元，而平均住院支出为6538欧元，导致单次PIPAC住院运营亏损622欧元。目前意大利国家卫生系统对PIPAC治疗的报销仅能部分覆盖医院成本。通过建立专项编码并将PIPAC正式认定为腹膜癌病的标准治疗方案，制定合理的报销机制至关重要。
肿瘤(癌症)患者之家